High Prevalence of Hypothyroidism and Approval and Launch of New Products to Augment Growth of Liothyronine Market

Liothyronine


 Liothyronine is used to treat an underactive thyroid (hypothyroidism) and myxedema coma. It is a manufactured form of the thyroid hormone triiodothyronine.

Market Dynamics

High prevalence of hypothyroidism is expected to propel growth of the global liothyronine market. For instance, the study ‘Prevalence of hypothyroidism in patients with type 2 diabetes mellitus and hypertension in India: a cross-sectional observational study’, reported that the prevalence of hypothyroidism in patients with type 2 diabetes mellitus, hypertension, and type 2 diabetes mellitus + hypertension was 24.8%, 33.5%, and 28.9%, respectively.

High prevalence of diabetes is also expected to aid in growth of the global liothyronine market. For instance, according to the study, “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045.   

Side effects of liothyronine are expected to hinder growth of the global liothyronine market. Excessive doses of liothyronine may lead to side effects such as weight loss, fever, headache, anxiety, trouble sleeping, arrhythmias, and heart failure. Moreover, recall of products is also expected to limit the market growth. For instance, in January 2020, Wockhardt UK Ltd recalled specific batches of levothyroxine 100micrograms/5ml oral solution due to notification of the impurity liothyronine exceeding the specification limit. Similarly, in August 2018, Westminster Pharmaceuticals, LLC recalled Levothyroxine and Liothyronine tablets in 15 mcg, 30 mcg, 60 mcg, 90 mcg and 120 mcg doses over ingredient concerns.

Competitive Analysis

Major players operating in global liothyronine market include, LGM Pharma, LLC, HBCChem, Inc., EMMX Biotechnology LLC, Zydus Cadila, Wockhardt UK Ltd. Toronto Research Chemicals, 3B Scientific, Apollo Scientific Ltd, American Biochemicals Inc., Acros Organics B.V.B.A, Suzhou Ryan Pharmaceutical Technology Co, ITL Pharma, Inc, Bioiberica S.A.U, and Titan Pharmaceuticals, Inc.

Major players operating in global liothyronine market are focused on approval and launch of new products to expand their product portfolio. For instance, in January 2021, Zydus Cadila received the U.S. Food and Drug Administration approval for marketing Liothyronine Sodium Tablets USP, 5 mcg, 25 mcg, and 50 mcg for the treatment of hypothyroidism.

Comments

Popular posts from this blog

Bourbon Whiskey Is the Most Popular Whiskey in America and In Many Other Countries around the World

Viral Vectors And Plasmid DNA Manufacturing Market Is Gaining Major Traction With Oxford Biomedica Plc Entering Into A 3-Year Agreement With Boehringer Ingelheim For The Manufacture And Supply Of Various Types Of Viral Vectors

Hard Surface Flooring Market Is Expected To Witness Robust Growth As Mohawk Industries Introduces Newly Imagined 30,000-Square Foot Floor Space At The International Surface Event (TISE)